Revolution Medicines Advances Pancreatic Cancer Drug

STAT News reports that Revolution Medicines has started shipping an experimental pancreatic cancer drug, daraxonrasib. The company plans to submit the drug for FDA approval soon, marking a significant step in cancer research.